NMS-1286937 - CAS 1034616-18-6
Catalog number: 1034616-18-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Polo-like Kinase (PLK)
NMS1286937, also know as NMS-P937, is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor NMS-1286937 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressing tumor cells. PLK1 is a serine/threonine protein kinase crucial in the regulation of mitosis.
Solid powder
PCM-075; PCM 075; PCM075; NMS1286937; NMS 1286937; NMS-1286937; NMS-P937; NMS-P-937; NMS-P 937; Onvansertib
Canonical SMILES:
Current Developer:
Nerviano Medical Sciences.
1.Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Sero V;Tavanti E;Vella S;Hattinger CM;Fanelli M;Michelacci F;Versteeg R;Valsasina B;Gudeman B;Picci P;Serra M Invest New Drugs. 2014 Dec;32(6):1167-80. doi: 10.1007/s10637-014-0158-6. Epub 2014 Sep 7.
BACKGROUND: ;Polo-like kinase 1 (PLK1) has emerged as a prognostic factor in various neoplasms, but only scarce data have been reported for high-grade osteosarcoma (OS). In this study, we assessed PLK1 expression and the efficacy of PLK1 inhibitor NMS-P937 in OS.;METHODS: ;PLK1 expression was assessed on 21 OS clinical samples and on a panel of human OS cell lines. In vitro efficacy of NMS-P937 was evaluated on nine drug-sensitive and six drug-resistant human OS cell lines, either as single agent or in combination with the drugs used in chemotherapy for OS.;RESULTS: ;PLK1 expression was higher in OS clinical samples and cell lines compared to normal human tissue. A higher PLK1 expression at diagnosis appeared to be associated with an unfavourable clinical outcome. PLK1 silencing produced growth inhibition, cell cycle retardation and apoptosis induction in human OS cell lines. NMS-P937 proved to be highly active in both drug-sensitive and drug-resistant cell lines, with the only exception of ABCB1-overexpressing, Doxorubicin (DX)-resistant variants. However, in these cells, the association of NMS-P937 with DX was able to revert DX-resistance by negatively interfering with ABCB1 transport activity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Polo-like Kinase (PLK) Products

CAS 40533-25-3 Cyclapolin 9

Cyclapolin 9
(CAS: 40533-25-3)

Cyclapolin 9 is a selective, ATP-competitive polo-like kinase 1 (PLK1) inhibitor with IC50 value of 500 nM. It is selective against a panel of 20 kinases.

CAS 929095-23-8 GSK 461364 analogue I

GSK 461364 analogue I
(CAS: 929095-23-8)

GSK 461364 analogue I is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 630 nM).

CAS 794466-17-4 DAP-81

(CAS: 794466-17-4)

DAP-81 is a diaminopyrimidine derivative that targets PLKs, destabilizing kinetochore microtubules. Other spindle tubules are stabilized, resulting in monopolar...

CAS 1082739-92-1 TC-S 7005

TC-S 7005
(CAS: 1082739-92-1)

TC-S 7005 is a potent and selective polo-like kinase 2 (PLK2) inhibitor (IC50 = 4 nM) with selectivity over PLK3 and PLK1 (IC50 = 24 and 214 nM, respectively). ...

CAS 755038-65-4 Volasertib

(CAS: 755038-65-4)

BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk) with an IC50 of 0 .87 nM and EC50 of 11-37 nM on a panel of cancer cell lines, w...

CAS 660868-91-7 GW843682X

(CAS: 660868-91-7)

GW843682X is a cell-permeable thiophene-benzimidazole compound that acts a selective PLK1 and PLK3 inhibitor with IC50s of 2.2 nM(PLK1) and 9.1 nM(PLK3).

CAS 1798871-30-3 Centrinone

(CAS: 1798871-30-3)

Centrinone, a pyrimidinamine derivative, has been found to be a high affinity and selective PLK4 inhibitor (Ki = 0.16 nM).

CAS 929095-18-1 GSK-461364

(CAS: 929095-18-1)

GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kin...

Chemical Structure

CAS 1034616-18-6 NMS-1286937

Quick Inquiry

Verification code

Featured Items